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INTRODUCTION
Thrombotic thrombocytopenic purpura (TTP) is a rare
hematologic syndrome. It is a multisystem disorder
characterized by microangiopathic hemolytic anemia and
thrombocytopenia and may be accompanied by fever and
renal or neurologic abnormalities (1,2). Most adult patients
acquire (3) the disease as a result of autoantibodies against
ADAMTS13 (i.e., idiopathic TTP), or it is observed in
association with collagen vascular disease, bone marrow
transplantation, systemic sclerosis, infections, polymyosi-
tis, pregnancy, or drug treatment, including cyclosporine,
tacrolimus, ticlopidine, and antineoplastic agents (i.e., non-
idiopathic TTP) (1,4). However, TTP associated with
mitral valve replacement surgery has not been reported.
In this paper, we describe a case of a 41-year-old
female who developed acute TTP after mitral valve
replacement surgery. The patient was treated with plasma
exchange (PE) and recovered following an uneventful
course.
CASE DESCRIPTION
A 41-year-old woman with a four-year history of shortness
of breath and chest tightness was admitted to our hospital for
evaluation. Echocardiography revealed mitral valve stenosis
(mitral valve area 1.06 cm2) as a result of rheumatic heart
disease. The patient underwentmitral valve replacement via a
right atriotomywith amechanical mitral valve (tissue annulus
diameter of 27 mm; St. Jude Medical, St. Paul, Minnesota
USA). Cardiopulmonary bypass lasted for 115 minutes, and
the aortic clamp time was 43 minutes. Postoperative
echocardiography revealed satisfactory valve function and
confirmed the successful removal of the intracavitary lesion.
Cefoxitin (3 g/day) was initiated on postoperative day 1
for prophylaxis. A complete blood count (CBC) was obtained
daily and revealed a low platelet count (Table 2) on day 2.
Platelets (400 ml) were transfused, but the patient developed
fever (Table 1), and the platelet count dropped continuously
(Table 2). In addition, the patient developed neurological
symptoms and subcutaneous ecchymosis. A blood biochem-
ical analysis revealed a serum lactate dehydrogenase of
821 U/L and 7.7 mmol/L total bilirubin (direct bilirubin,
2.1 mmol/L; indirect bilirubin, 5.6 mmol/L). Her urine exam
was positive for protein (3+), leukocytes (normal), hemoglo-
bin (2+), and bilirubin (1+). A direct Coombs test was
negative, and PT and aPTT were within the normal range.
Liver and renal function tests were normal. Physical
examinations of the cardiovascular and respiratory systems
and abdomen were normal. Abdominal ultrasonography,
computed tomography, and magnetic resonance imaging of
the brain revealed no abnormalities. The patient was
diagnosed with acquired TTP and received a bolus of
dexamethasone (10 mg), an infusion of a high volume of
fresh frozen plasma, and a red blood cell transfusion.
However, the patient did not respond adequately. Until
eight hours after one-volume (2000 ml fresh frozen plasma)
PE was treated, the patient’s body temperature began to
normalize, and her neurologic and respiratory parameters
improved. The patient was discharged after an additional
eight days of hospitalization without plasma exchange.
DISCUSSION
TTP is a rare hematologic emergency with an abrupt
onset, and it is potentially fatal. It is clinically characterized
by five typical symptoms: hemolytic anemia, thrombocyto-
penia, renal impairment, fever, and neurological disorders.
Although TTP is associated with a severe deficiency of
ADAMTS13 activity (5), measurements of ADAMTS13
activity are not required to conclusively confirm the
diagnosis (6). Therefore, the diagnosis of TTP is based on
the presenting clinical features (1). As in this case, there is
typically insufficient time to evaluate ADAMTS13 activity,
and a prompt diagnosis of TTP is critical for initiating
treatment and reducing patient mortality.
Mitral valve replacement is one of the best treatments for
mitral stenosis. It has been performed successfully with
excellent results and limited complications. The major
complications of mitral valve replacement surgery include
postoperative bleeding, ischemic stroke, myocardial infarc-
tion and death. This is the first case report of TTP as a
complication of mitral valve replacement surgery. Although
ADAMTS13 activity was not measured in our case, the
clinical course was not affected by PC transfusion, and the
rapid response to plasma exchange supports the TTP
diagnosis. We will follow up this case and evaluate plasma
ADAMTS13 activity and autoantibodies to exclude the
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possibility of hereditary ADAMTS13 deficiency, which is
extremely rare, or acquired autoantibodies against
ADAMTS13, which often persist despite clinical resolution
or remission (7).
Daily plasma exchange remains the mainstay of treat-
ment for acquired TTP regardless of its etiology (1).
However, plasma infusion once every two weeks appears
to be sufficient for hereditary TTP (8). Our patient
recovered with one plasma volume and showed a good
clinical outcome, with a normal temperature and improve-
ment of neurological and respiratory parameters eight
hours later. The course over the next eight days of
hospitalization was uneventful and did not require a
second plasma exchange.
Although the occurrence of TTP associated with mitral
valve replacement surgery is extremely rare, it is important to
recognize TTP as a cause of thrombocytopenia and hemolytic
anemia in any patient with mitral valve replacement surgery.
The prompt initiation of treatment with plasma exchange
remains the cornerstone of TTP treatment. Despite the
prognosis of TTP associated with mitral valve replacement
surgery, the schedule for PE remains poor, and further
studies are necessary to improve the management of this
disease.
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